Abstract Background: Psoriasis vulgaris is a chronic immune-mediated skin disorder characterized by keratinocyte hyperproliferation and T-cell-driven inflammation. Recent evidence suggests a potential role of gasdermin family proteins, particularly Gasdermin B (GSDMB), and the proinflammatory cytokine Interleukin-17A (IL-17A) in its pathogenesis. Aims and Objectives: To assess the gene expression levels of GSDMB and Interleukin-17A in patients with psoriasis vulgaris and explore their relationship with disease severity. Patients and Methods: This case-control study included 150 subjects: 75 patients with plaque psoriasis and 75 age- and sex-matched healthy controls. Disease severity was assessed using the psoriasis area and severity index (PASI). Quantitative real-time polymerase chain reaction was performed on peripheral blood samples to measure GSDMB and IL-17A mRNA expression. Results: The expression levels of both GSDMB and IL-17A were significantly elevated in psoriasis patients compared with controls ( P = 0.005 and P = 0.001, respectively). Higher gene expression levels were observed in cases with severe psoriasis, with significant correlations between GSDMB and PASI (r = 0.336, P = 0.003), and IL-17A and PASI (r = 0.260, P = 0.024). A strong positive association was also noted between GSDMB and IL-17A expression (r = 0.327, P = 0.004). Limitations: Small sample size and estimation of gene expression in blood, not in skin lesions. Conclusion: Psoriasis vulgaris is associated with significant upregulation of GSDMB and IL-17A gene expression. These markers may serve as reliable indicators of disease presence and severity, supporting their potential role as diagnostic and prognostic biomarkers in psoriasis.
Abstract Background: Alopecia significantly affects psychological well-being and social functioning. Standard treatments, like minoxidil and finasteride, are limited by delayed efficacy, need for lifelong use, and adverse effects. Prostaglandin analogs (PGAs), originally developed for ocular hypertension, have shown promise in promoting hair growth. This study compares their effects with minoxidil in a murine model. Aim and Objectives: To compare the effects of bimatoprost, latanoprost, and travoprost on hair growth in C57BL/6 mice, with evaluation of hair density, follicle diameter, and growth rate using minoxidil as the comparator. Materials and Methods: After Institutional Animal Ethics Committee approval, 40 male C57BL/6 mice (aged 6–7 weeks, weighing 20–25 g) were randomized into five groups ( n = 8 in each group): (1) vehicle control, (2) minoxidil 5%, (3) latanoprost 0.005%, (4) bimatoprost 0.03%, and (5) travoprost 0.004%. Drugs were applied topically to shaved dorsal skin daily for 28 days. Hair growth was assessed by follicle density, bulb diameter, and area of regrowth using ImageJ from photographs taken on days 1, 7, 15, and 28. Results: All PGAs significantly increased hair density compared to vehicle control (vehicle control: 1.50 ± 0.55 vs. latanoprost: 7.50 ± 1.69, bimatoprost: 7.75 ± 2.87, travoprost: 6.87 ± 3.40; P = 0.001). Latanoprost and bimatoprost showed higher hair density than minoxidil (3.75 ± 2.87; P = 0.038 and 0.010, respectively). Hair follicle diameter was greater with PGAs (latanoprost: 53.12 ± 5.30, bimatoprost: 51.87 ± 7.52, travoprost: 48.12 ± 3.47 µm) versus vehicle control (27.91 ± 5.57 µm, P = 0.001) and minoxidil (38.12 ± 5.46 µm, P = 0.001). Bimatoprost showed the greatest regrowth by day 28, while latanoprost demonstrated earlier onset by day 15. PGAs also caused darker pigmentation and longer hair. Limitations: The present study duration was limited to 4 weeks. Minoxidil (positive control) did not show noticeable hair growth because its effects usually take 6–8 weeks to appear. Conclusion: Topical PGAs improved key hair growth parameters. Bimatoprost and latanoprost showed early and superior efficacy by day 28.
